Clarkston Consulting https://www.facebook.com/ClarkstonConsulting https://twitter.com/Clarkston_Inc https://www.linkedin.com/company/clarkston-consulting http://plus.google.com/112636148091952451172 https://www.youtube.com/user/ClarkstonInc
Skip to content

DSCSA Enforcement Delay – What It Means for You

On June 30, 2017, the FDA published a draft guidance announcing an enforcement delay for the pharmaceutical manufacturer’s requirement under the Drug Supply Chain Security Act (DSCSA). The delay pushes enforcement back a full year from November 27, 2017 to November 27, 2018.

The delay was issued in response to requests from many smaller contract manufacturing organizations (CMOs), who contended that they simply could not have the line equipment, hardware, and software ready for serialization packaging by the deadline.

Needless to say, many manufacturers are greeting the FDA guidance for delayed enforcement with sighs of relief.  Other firms, having prepared for the original deadline, may be tempted to regret the intensity (and cost) of their efforts to comply with the law.  But looking beyond these immediate reactions, what are the implications of this postponement?

The Law Has Not Changed

Quoting the FDA guidance text:

“ … manufacturers are to begin including a product identifier on prescription drug packages and cases on November 27, 2017, the FDA is delaying enforcement of those requirements until November 2018 to provide manufacturers additional time and avoid supply disruptions.”

The key point is that pharma manufacturers are still required to begin serialization by the November 27, 2017 deadline.  The fact that it will not be enforced for a year does not relieve manufacturers of this obligation.  That said, non-compliance is without any penalty or regulatory fine.

Don’t Lose Focus

With this delay, the FDA assumes that manufacturers unable to meet the 2017 deadline are making, and will continue to make, a good faith effort to comply with the DSCSA as soon as possible.

One of the frequently-cited reasons in the requests for delay is the long lead times and scarcity of experienced technicians for the L1/L2/L3 serialization equipment.  Wisdom lies in prompt initiation or continuation of current efforts to obtain and implement these serialization systems.  If anything, one can reasonably expect demand for these systems and services to increase, especially as the new 2018 delayed deadline approaches.   The delay will certainly reduce demand from the manufacturers that have completed or are completing their implementations, but such alleviation may be more than offset by the demand from other firms that have not yet started or are just beginning their serialization projects.

Assuming a six-month period of buffer time from November 27, 2018 (to allow for lead time, scheduling, and testing uncertainties) would establish a target completion date of May 28, 2018.   Implementation for a single packaging line will require between six and nine months.   Considering these factors together, serialization work must begin by October – December 2017, without exception. Anything beyond this would put your business in jeopardy from a range of regulatory, legal, and financial penalties and risks – all the more egregious given the FDA’s delay.

Compliance vs. Other Business Benefits

For some, the FDA’s delay is an opportunity to leverage serialization efforts for business benefits beyond simple compliance.   Several manufacturers are already integrating with serialized data exchanges to wholesalers and repackagers.  Using this time, serialization-ready manufacturers can pilot and establish the data exchanges ensuring a safer supply chain and returns tracking data.   Additionally, serialization provides benefits as the serial number is incorporated into the chargeback accounting and processes.  Thus, the delay allows for more integration with key wholesalers and establishing serialization-ready manufacturers as preferred trading partners.

Alternative Compliance Strategies

Some L1/L2/L3 vendors have urged manufacturers to consider implementing serialization and not serialization with aggregation at least to begin with.  Although the DSCSA does not itself require aggregation, the “Big 3” U.S. wholesalers have stated that they will require aggregation from manufacturers as a condition of doing business.  Clearly, aggregation is highly desirable. Keep in mind, however, that a serialization implementation can typically be accomplished in approximately half the time as a serialization with aggregation implementation.

Manufacturers having trouble meeting the deadline may also consider various alternatives. Many manufacturers may try subcontracting to CMOs that are or will be ready for serialization. Others may utilize off-line serialization if their packaging lines cannot be ready in time.  Both options involve higher operating costs and the offline option may not be viable for large product volumes, but either or both may be possible on a short-term basis.

Some manufacturers have elected to serialize only one of several packaging lines.   Non-serialized products are packaged on the non-serialized lines; then all semi-finished products are transferred to the serialized line to add the serialization-mandated 2D matrix and human readable data to the packages.  This approach has the advantage of establishing serialization capability and lower cost but requires careful assessment of the risk of not having sufficient serialization capacity to handle product volumes.

The delay for enforcement does now also give manufacturers the opportunity to include aggregation in their serialization plans and still make the November 2018 date.  Analysis shows that serialization and a subsequent aggregation is more expensive in total, than doing serialization and aggregation together.  This new guidance provides the time to allow a consolidated project with both serialization and aggregation.  Thus, providing the business the ability to finish the serialization project and move to regular operations sooner.

Keep Calm and Carry On

Manufacturers whose efforts are nearing completion should continue their efforts and resist the temptation to slow down.  Getting systems in place, in accordance with pre-delay plans, will ensure serialization capability and free up serialization resources in an orderly way.  If aggregation wasn’t part of the original plan, then consider incorporating now.

Manufacturers that will need the delay to comply with the DSCSA should continue or commence their efforts posthaste.  For more information about getting started (and all things serialization) be sure to check out Clarkston’s serialization insights or feel free to contact me directly using the contact information at the top of this page.

If you would like to read more from our Serialization experts, subscribe to our blog to receive the latest insights:

Subscribe to Clarkston's Insights

  • I'm interested in...
  • Clarkston Consulting requests your information to share our research and content with you.

    You may unsubscribe from these communications at any time.

  • This field is for validation purposes and should be left unchanged.

Co-authors and contributors: Don Eberts, Dave Treadaway, and Megan Weldon

Tags: Serialization & Traceability
RELATED INSIGHTS